



Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist

Henry A. Nasrallah ^{*}, Rissa Fedora, Robert Morton

Saint Louis University, Department of Psychiatry and Behavioral Neuroscience, St. Louis, MO, United States of America

ARTICLE INFO

Article history:

Received 7 January 2019

Received in revised form 20 February 2019

Accepted 25 February 2019

Available online 2 March 2019

Keywords:

Schizophrenia

Refractory hallucinations and delusions

Clozapine

Pimavanserin

Serotonin 5HT-2A inverse agonist

ABSTRACT

Background: Clozapine was the widely accepted gold standard treatment for treatment resistant psychotic symptoms. Clozapine has efficacy of about 50% and some responding patients have to discontinue it due to serious adverse effects. The search for novel agents to use for clozapine-non-responders continues. One such possible agent is the non-dopaminergic antipsychotic pimavanserin, an inverse agonist of serotonin 5-HT_{2A} receptors which was recently approved for the hallucinations and delusions of Parkinson's Disease Psychosis. We report here the successful results of using pimavanserin in patients with refractory hallucinations and delusions who failed to respond to clozapine. We also report similar results in refractory psychosis patients who did not receive clozapine.

Methods: We present ten cases of patients with schizophrenia and schizoaffective disorder with refractory hallucinations and delusions who received a trial of pimavanserin when clozapine or multiple antipsychotics failed. Six of ten patients had not responded to a clozapine trial. The subjects' ages ranged between 21 and 77 years and were followed up for several months.

Results: All 10 patients with refractory hallucinations and delusions showed marked response to pimavanserin 34 mg/day within 4–8 weeks, with continuation of the response for several months of follow-up. Improvements in negative symptoms and social functioning were also observed in several patients.

Discussion: This series of 10 cases of patients with refractory psychosis who responded to pimavanserin is an important new finding that has never been reported before. Controlled studies comparing clozapine and pimavanserin in refractory schizophrenia are warranted to confirm these clinical observations.

© 2019 Elsevier B.V. All rights reserved.

1. Introduction

Clozapine is widely recognized as the last resort agent for persistent hallucinations and delusions that are refractory to first or second generation antipsychotic drugs (Meltzer, 1997; McEvoy et al., 2006). A significant proportion of patients with schizophrenia are estimated to be treatment-resistant or refractory to multiple antipsychotics (Siskind et al., 2017), which makes clozapine a vital part of the psychopharmacological toolbox for the management of chronic schizophrenia.

However, response to clozapine in treatment-resistant/refractory psychosis is limited and estimated to be about 40% of cases (Siskind et al., 2017), leaving a large segment of refractory psychosis cases with no viable alternative. Researchers have reported several adjunctive agents that may improve clozapine-resistant refractory hallucinations and delusions including Lamotrigine (Tiuhonen et al., 2009) and Sodium Benzoate (Lin et al., 2017). However, there are still no widely accepted

adjunctive pharmacotherapies for clozapine non-responders, and certainly no alternatives to clozapine itself in refractory psychosis.

Pimavanserin, an inverse agonist of the serotonin 5HT-2A receptor and to a lower extent 5HT-2C receptor (Meltzer et al., 2010), was recently approved for the treatment of the hallucinations and delusions that occur in up to 50% of patients with Parkinson's Disease (Hacksell et al., 2014). Since pimavanserin does not bind at all to dopamine D₂ receptors, it is the first non-dopaminergic antipsychotic since the discovery of the first dopamine antagonist, chlorpromazine, in the early 1950s. It is an ideal pharmacotherapy for Parkinson's Disease psychosis because it can treat the psychotic symptoms without exacerbating the motor symptoms of Parkinson's disease, which can be exacerbated with all current antipsychotic drugs because they all reduce dopamine neurotransmission.

Because pimavanserin has been demonstrated to exert efficacy on hallucinations and delusions in a major psychotic disorder like Parkinson's Disease Psychosis, it seems reasonable that it be used as we an adjunctive therapy to clozapine in desperately sick patients with refractory hallucinations and delusions who failed to respond to

^{*} Corresponding author.

E-mail address: henry.nasrallah@health.slu.edu (H.A. Nasrallah).

a trial of clozapine. We report here how that clinical strategy in a clinical setting of a residential treatment facility for patients with chronic psychotic disorders serendipitously revealed that the addition of pimavanserin to clozapine in patients with refractory hallucinations and delusions led to remission of the refractory psychotic symptoms which had failed to respond to several months of clozapine treatment. Following that important clinical observation in several patients pimavanserin was administered in monotherapy to patients with refractory hallucinations and delusions prior to using clozapine with the intention to resort to clozapine only if pimavanserin does not exert clinical efficacy on refractory psychosis.

2. Methods

This is a retrospective report of patients with refractory psychosis who responded to pimavanserin. Our clinical use of pimavanserin initially as adjunctive therapy and as subsequently as monotherapy for treatment-refractory psychosis was done as clinical management for desperately sick refractory patients, not as a research study. No rating scales are used in the residential treatment facility and improvement is determined clinically by the treating psychiatrist [RM] and documented as usual in the medical record. It was over a year later, after success was noted in several patients, that we felt it was important to report those encouraging findings in a peer reviewed journal so that other clinicians, and researchers, recognize the potential for pimavanserin to be a useful agent in refractory psychosis, even when clozapine, the only approved drug for this condition, fails to suppress refractory hallucinations and delusions.

Thus, those clinical findings ended up serving as a hypothesis-generating observations which may very well set the stage for a controlled trial, now that pimavanserin's efficacy was clinically achieved in refractory patients with or without clozapine. Treatment resistant and refractory schizophrenia is a significant unmet need in psychiatry, and serendipitous findings like this one may lead to a new avenue for treating what is regarded as the most severe forms of psychosis.

3. Results

Pimavanserin did demonstrate efficacy as adjunctive therapy to clozapine-non-responding psychotic symptoms in 6 patients. Pimavanserin was also administered as monotherapy to 4 patients with refractory hallucinations and delusions who had not received clozapine, and observed strong efficacy there as well with very good tolerability and safety after several months of treatment, unlike the serious adverse effects often encountered with clozapine.

The following are brief vignettes of all 10 cases. Detailed clinical data are available on all patients but were not included here due to space considerations. No serum clozapine levels were obtained at the residential treatment facility. In addition, none of the patients is a smoker, so there was no potential reduction of clozapine serum concentrations due to the induction of Cytochrome 1A2 by nicotine.

3.1. Efficacy of pimavanserin as adjunctive therapy with clozapine

The following are 6 brief vignettes of clinical remission of refractory hallucinations and delusions when pimavanserin was added as adjunctive therapy to patients with poor or partial response to clozapine in adequate doses after several months. Interestingly, it was noted that some of the negative symptoms of the patients also improved concurrently with the elimination of the refractory positive symptoms:

3.1.1. Case 1

44-year-old female with auditory and visual hallucinations since age 18, along with severe paranoid delusions. She was started on clozapine 400 mg/day for several months after failing to respond to various antipsychotics, but responded only partially and her hallucinations

persisted. Pimavanserin 34 mg/day was then added. Her visual hallucinations disappeared in 1 month, and her auditory hallucinations responded completely after 2 months. In addition, she was also noted to become more friendly, pleasant and less isolative.

3.1.2. Case 2

21-year old male with intense auditory and visual hallucinations, and severe delusions that led him to “argue with inanimate objects”. Clozapine 500 mg/day was started but failed to control his hallucinations or delusions after several weeks. Pimavanserin 34 mg/day was added. His hallucinations remitted fully after 1 month. He also became more sociable and his affect became much less blunted.

3.1.3. Case 3

40-year old male with refractory auditory hallucinations but no visual hallucinations. His command auditory hallucinations prompted him to kill himself. He received multiple antipsychotics and experienced severe EPS. So, he was switched to clozapine 200 mg/day, but continued to receive olanzapine, risperidone, ziprasidone and loxapine, but with no response. Pimavanserin 34 mg/day was then started, and his auditory hallucinations noticeably improved within 1 months, and were completely gone after 2 months. His affect became brighter and he became more friendly and “much happier”.

3.1.4. Case 4

54-year old male with both auditory and visual hallucinations. He did not respond to several antipsychotics. A trial of clozapine 500 mg/day failed to help him and his hallucinations actually worsened after a few months. Addition of olanzapine 30 mg/day did not help either. Pimavanserin 34 mg/day was then added. His auditory hallucinations decreased within 1 month, and both auditory and visual hallucinations completely disappeared at the end of 2 months. He also became more sociable, with improved cognitive ability, and even started working part-time.

3.1.5. Case 5

68-year old male with visual hallucinations and comorbid auditory hallucinations telling him to commit suicide. He sustained several injuries by repeatedly hitting his ears and head. After failing to respond to various antipsychotics for many years, he was started on clozapine 350 mg/day, but with minimal response after several months. Pimavanserin 34 mg/day was then added. His auditory hallucinations decreased after 1 month, and by 3 months he was hitting his head much less frequently (1/week instead of 9 times/week). His hallucinations and head hitting completely disappeared after 5 months. He was also noted to become more social and engaged with much less flat affect and he felt “happier”.

3.1.6. Case 6

61-year old female, with command (suicidal) auditory hallucinations. After failing to respond to many antipsychotics and suffering from EPS, she was given Clozapine that was titrated up to 800 mg/day with no remission of her auditory hallucinations after several months. Pimavanserin 34 mg/day was added. Her auditory hallucinations gradually faded and stopped completely after 2 months. She became more verbal and less aggressive, with a brighter affect.

3.2. Pimavanserin monotherapy in refractory psychosis

The following are 4 brief vignettes of remission of refractory hallucinations and delusions with Pimavanserin when used in patients who had never received Clozapine:

3.2.1. Case 1

44-year-old female with schizoaffective disorder and tardive dyskinesia, who suffered from refractory auditory hallucinations. She also

had a flat affect. She received multiple antipsychotic trials including oral paliperidone 12 mg/day and later iloperidone 8 mg BID and quetiapine 900 mg a day, but her hallucinations persisted. Pimavanserin 34 mg a day was then started. Her auditory hallucinations disappeared within 4 weeks. In addition, her negative symptoms showed improvement as well and she started initiating conversations, which she had not done before. 2-year follow-up showed continued absence of auditory hallucinations. She also showed more spontaneity, less blunting of affect and more social interactions.

3.2.2. Case 2

69-year old female with schizophrenia and auditory hallucinations, living in a group home since age 52. She had ongoing yelling and screaming at the voices, which frequently ordered her to tear up and throw objects, but did not order her to harm herself or others. Several antipsychotics failed to help her including olanzapine 25 mg /day for several years, long-acting injectable paliperidone 234 mg/month, and haloperidol decanoate 75 mg/month. She was started on pimavanserin 34 mg/daily. Within 2 weeks, her screaming and yelling at the voices stopped and no auditory hallucinations occurred over the next several months. She also started to come out of her room and mingle with other patients, which she had not done before.

3.2.3. Case 3

77-year old male with schizophrenia paranoid type and intellectual disability. He had a history of auditory and visual hallucinations as well as disrobing in public, and displaying belligerence and argumentative behavior. His verbal language was limited. He isolated himself and had a flat affect. He often tore up his room in response to the voices of “the demons”. Staff often observed him talking to the closet in his room. A trial of risperidone 3 mg/ day for several months had no efficacy. He was started on pimavanserin 34 mg QHS and risperidone was tapered off. Both his auditory and visual hallucinations disappeared 4–5 weeks after starting pimavanserin, and the response continued over the next 8 months. He became much less aggressive, more outgoing, and more compliant with staff's requests. He also became more interactive with his peers and residential facility staff.

3.2.4. Case 4

55-years old female with schizoaffective disorder. She had auditory and visual hallucinations for many years. Her psychotic symptoms failed to respond to aripiprazole or olanzapine at escalating doses. She was also receiving clomipramine 50 mg qid for OCD. In addition to the hallucinations, she also had an intense delusion that people are trying to harm her. She was started on pimavanserin 34 mg daily. Her auditory hallucinations were completely gone in 1 month. Visual hallucinations diminished at 1 month but disappeared completely after 2 months. She remained free of hallucinations over the following year, and she did not complain of side effects. Her mood also improved, she became more cooperative with staff and started socializing with other patients. She seemed less disgruntled and her attention also improved.

4. Discussion

This non-research clinical series of 10 patients with refractory psychotic symptoms showed very encouraging results for Pimavanserin on two fronts: As adjunctive therapy to clozapine-resistant patients, and as a monotherapy alternative to clozapine.

Given the many safety and tolerability adverse effects of clozapine and the relatively benign side-effect profile of Pimavanserin, a case can be made (assuming replication of our findings in a placebo-controlled study) that Pimavanserin may emerge as a safer alternative to clozapine in refractory psychosis, with clozapine [with the required weekly white blood count and multiple tolerability and safety issues] remaining as a last resort if Pimavanserin does not work. Agranulocytosis (requiring weekly blood draws for WBC count), cardiomyopathy,

ileus, diabetic keto-acidosis and seizures can be life-threatening side-effects associated with clozapine, and the tolerability problems include extreme sedation, sialorrhea, constipation, weight gain and hypotension (Raja and Raja, 2014; Citrome et al., 2016). On the other hand, the side-effects of Pimavanserin, as reported in the FDA trial that led to its approval for Parkinson's disease psychosis (Cummings et al., 2014) included peripheral edema (2.3%), asthenia (2.1%), confusional state (2.3%), somnolence (2.1%), insomnia (2.3%). We did not have to discontinue Pimavanserin on any of the patients in our case series due to safety or tolerability concerns.

An important implication from our finding proposes that inverse agonism of 5HT-2A and 5 HT-2C receptors can exert efficacy on psychotic symptoms that traditionally, and for decades, have been assumed to respond only to dopamine D2 receptor antagonists. Clozapine is a dopamine antagonist, albeit weakly so, but has strong serotonin 5 HT-2A and serotonin 5 HT-2C antagonist activity. Psychosis has been hypothesized to be associated with a dysfunction in brain serotonin 5HT-2C receptors and that atypical antipsychotics exert inverse agonist effects on the 5HT-2C receptors, in addition to strong antagonistic effect on the serotonin 5HT-2A receptors (Herrick-Davis et al., 2000). Thus, serotonin pathways may play an important role in psychosis, but perhaps especially so in the subtype of schizophrenia with refractory hallucinations and delusions that are refractory to dopamine D2 receptor antagonism. This may explain why Pimavanserin has efficacy on refractory hallucinations and delusions even without any dopamine D2 receptor affinity, as all available first or second generation antipsychotics do.

Clozapine is mainly metabolized via the cytochrome 1A2 enzyme. Pimavanserin is metabolized via the cytochrome 3A4/5 enzymatic pathway, and it is not known to have any significant inhibition properties. Thus, its successful augmentation of clozapine is most likely a pharmacodynamics, not a pharmacokinetic effect.

The main limitation of this study is its retrospective nature, non-blind observations by the treating psychiatrist, lack of use of rating scales, and no measurements of clozapine serum concentration despite the use doses known to be in the therapeutic range. However, despite the lack of a pre-hoc hypothesis because the patients were treated in a non-research group-home settings, a very encouraging signal for the efficacy of pimavanserin in refractory schizophrenia was observed. Based on these results, IRB-approved double-blind, placebo controlled trials should be conducted to confirm the efficacy of pimavanserin in refractory psychosis as an initial alternative to clozapine with a safer side-effect profile. Given the improvement in the affect and socializations of the patients in addition to the suppression of refractory psychosis, future controlled trials should rate the improvement of negative symptoms as a second outcome measure to confirm the observations made in those patients whose refractory psychosis responded very well to pimavanserin. Finally, the controlled studies should prospectively document the adverse effects of pimavanserin as well as the proportion and characteristics of refractory psychosis patients who do not respond to pimavanserin and whether such patients do or do not respond to clozapine.

5. Conclusions

The clinical findings of our open label 10 cases series of the efficacy of pimavanserin as an adjunctive treatment to clozapine-non-responsive refractory psychosis ($N = 6$) or as monotherapy in lieu of clozapine in refractory psychosis ($N = 4$), could have important implications for the management of the clinical subtype of the heterogeneous schizophrenia syndrome with hallucinations and delusions that are refractory to the traditional dopamine D2 receptor antagonist class of antipsychotics, whether first or second generation. Double-blind, placebo controlled trials of pimavanserin in refractory schizophrenia are certainly warranted, given these findings. It would also be interesting to test pimavanserin in first-episode psychosis to identify a “serotonergic subtype” of the schizophrenia syndrome but also to completely avoid

the extrapyramidal side-effects (EPS) of dopamine antagonists, to which first-episode psychosis patients are especially susceptible. The complete lack of dopamine D2 receptor antagonism makes pimavanserin the ultimate “atypical” antipsychotic because even clozapine, which has practically no acute EPS effects, is still associated with tardive dyskinesia risks after long-term use (Carbon et al., 2018). Of note is that Pimavanserin was recently reported in a double-blind placebo-controlled trial to improve the psychotic symptoms associated with Alzheimer’s Disease (Ballard et al., 2018), which is not considered as a dopaminergic psychosis.

Conflict of interest

Nasrallah: Advisory Boards, consultant and speaker's bureau: Acadia, Alkermes, Allergan, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Teva.

Fedora: None.

Morton: Advisory Board: Neurocrine. Speaker's bureau: Acadia, Alkermes, Neurocrine, Sunovion.

Contributors

Dr. Morton administered the medications.

Dr. Nasrallah wrote the article.

Dr. Fedora summarized the case vignettes from the medical notes.

Role of funding

There was no outside funding for this project.

Acknowledgements

None.

References

Ballard, C., Banister, C., Khan, Z., Cummings, J., Demos, G., Coate, B., Youakim, J.M., Owen, R., Stankovic, S., Investigators, A.D.P., 2018. Evaluation of the safety, tolerability, and

efficacy of Pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. *Lancet Neurol.* 17, 213–222.

Carbon, M., Kane, J.M., Leucht, S., Correll, C.U., 2018. Tardive dyskinesia risk with first and second generation antipsychotics in comparative randomized controlled trials: a meta-analysis. *World Psychiatry* 17, 330–340.

Citrome, L., McEvoy, J.P., Saklad, S.R., 2016. Guide to the management of clozapine-related tolerability and safety concerns. *Clin. Schizophr. Relat. Psychoses* 10, 163–177.

Cummings, J., Isaacson, S., Mills, R., Williams, H., Chi-Burris, K., Corbett, A., Dhall, R., Ballard, C., 2014. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. *Lancet* 383, 533–540.

Hackzell, U., Burstein, E.S., McFarland, K., Mills, R.G., Williams, H., 2014. On the discovery and development of Pimavanserin: A Novel Drug Candidate for Parkinson's Disease psychosis. *Neurochem Res* 39, 2008–2017.

Herrick-Davis, K., Grinde, E., Teitler, M., 2000. Inverse agonists activity of atypical antipsychotic drugs at human 5-hydroxytryptamine 2C receptors. *J. Pharmacol. Exp. Ther.* 295, 226–232.

Lin, C.H., Lin, C.H., Chang, Y.C., Huang, Y.J., Chen, P.W., Yang, H.T., Lane, H.Y., 2017. Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. *Biol. Psychiatry* 84, 422–432.

McEvoy, J.P., Lieberman, J.A., Stroup, T.S., Davis, S.M., Meltzer, Y., Rosenheck, R.A., Swartz, M.S., Perkins, D.D., Keefe, R.S., Davis, C.E., Severe, J., Hsiao, J.K., CATIE investigators, 2006. *Am. J. Psychiatry* 163, 600–610.

Meltzer, H.Y., 1997. Treatment-resistant schizophrenia: the role of clozapine. *Curr. Med. Res. Opin.* 14, 1–20.

Meltzer, H.Y., Mills, R., Revell, S., Williams, H., Johnson, A., Bahr, D., Friedman, J.H., 2010. Pimavanserin, a serotonin(2A) receptor inverse agonists, for the treatment of Parkinson's disease psychosis. *Neuropsychopharmacology* 35, 881–892.

Raja, M., Raja, S., 2014. Clozapine safety, 40 years later. *Curr. Drug Saf.* 9, 163–195.

Siskind, D., Siskind, V., Kisely, S., 2017. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. *Can. J. Psychiatr.* 62, 772–777.

Tiihonen, J., Wahlbeck, K., Kiviniemi, V., 2009. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. *Schizophr. Res.* 109, 10–14.